Device for measuring drug levels

By using a combination of control unit, sensor assembly and cap sensor in the drug delivery device, the problem of difficult to monitor the drug filling level is solved, and the accuracy and energy-saving effect of drug use are achieved.

CN113795288BActive Publication Date: 2024-11-08SANOFI SA(FR)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080034125.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-03-12
Filing Date
2020-03-10
Publication Date
2024-11-08
Estimated Expiration
2040-03-10

AI Technical Summary

Technical Problem

Existing drug delivery devices are difficult to effectively monitor and measure the filling level of the agent, resulting in improper use or waste of medication.

Method used

A device is designed, including a control unit, a sensor assembly and a cap sensor, which wakes up the control unit by detecting the removal and attachment of the cap, thereby starting to measure the filling level of the agent, and using a combination of a wireless communication module and an LED array light sensor to realize Accurate measurement of dosage in the drug container.

Benefits of technology

Provides a simple, intuitive and energy-efficient way to monitor the level of drug filling to ensure the accuracy and efficiency of drug use and reduce drug waste.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113795288B_ABST
    Figure CN113795288B_ABST
Patent Text Reader

Abstract

A device comprises: a control unit; a sensor assembly configured to measure a fill level of a medicament in a container of a drug delivery device; and a cap sensor configured to detect that a cap is at least partially removed from the drug delivery device; wherein the control unit is configured to be awakened from a dormant state in response to the cap sensor detecting that the cap has been at least partially removed from the drug delivery device, and wherein the sensor assembly is configured to start measuring the fill level after the control unit is awakened from the dormant state.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to an apparatus for measuring the fill level of a medicament in a reservoir of a drug delivery device. Background Art

[0002] There are many diseases that need to be treated regularly by injecting medicaments. This injection can be carried out by using an injection device, applied by medical staff or the patient himself. For example, type 1 and type 2 diabetes can be treated by the patient himself by injecting insulin dosage, such as once or several times a day. For example, a pre-filled disposable insulin injection pen can be used as an injection device. Alternatively, a reusable injection pen can be used. A reusable injection pen allows the empty medicament cartridge to be replaced with a new medicament cartridge. Any injection pen can be provided with a group of one-way needles, and the needle is replaced before each use. Then the insulin dosage to be injected can be manually selected, for example, on the insulin injection pen by turning the dosage knob and observing the actual dosage from the dosage window or display of the insulin injection pen. Then the dosage is injected by inserting the needle into the skin part and pressing the injection button of the insulin injection pen.

[0003] In order to be able to monitor insulin injection, for example to track the dose that has been injected, it is necessary to measure the filling level of the medicament in the injection device. In other words, it is desirable to measure the amount of medicament contained in the container of the injection device. Summary of the invention

[0004] According to a first aspect of the present disclosure, there is provided an apparatus comprising: a control unit; a sensor assembly configured to measure a fill level of a medicament in a container of a drug delivery device; and a cap sensor configured to detect that a cap is at least partially removed from the drug delivery device; wherein the control unit is configured to be awakened from a dormant state in response to the cap sensor detecting that the cap has been at least partially removed from the drug delivery device, and wherein the sensor assembly is configured to start measuring the fill level after the control unit is awakened from the dormant state. Thus, a simple, intuitive and energy-efficient method for determining the amount of medicament in a drug delivery device is provided.

[0005] The measurement of the fill level may be initiated in response to the cap sensor detecting that the cap has been at least partially removed from the drug delivery device.

[0006] The device may comprise a wireless communication module, and the measurement of the fill level may be initiated in response to the wireless communication module receiving a signal.

[0007] The device may be a supplemental device attachable to the drug delivery device.

[0008] The apparatus may be attachable to a cartridge holder of the drug delivery device, the cartridge holder being configured to accommodate the container.

[0009] The cap sensor may include at least one of a reed switch, a photodiode, and / or a mechanical switch.

[0010] The apparatus may comprise a collar, wherein the collar is configured to receive a cartridge holder of the drug delivery device through a hole of the collar.

[0011] The sensor assembly may be configured to measure the fill level through a window in a cartridge holder of the drug delivery device.

[0012] The sensor assembly may include an LED array and a light sensor, wherein the LED array and light sensor are configured to extend parallel to a longitudinal axis of the container.

[0013] The apparatus may include a wireless communication module and may be configured to transmit a signal from the wireless communication module to an external device, the signal including data representative of one or more fill level measurements made by the sensor assembly.

[0014] The measurement of the fill level may be stopped in response to the wireless communication module of the apparatus receiving a signal from the external device.

[0015] The measurement of the fill level may be stopped in response to the cap sensor detecting that the cap is reattached to the drug delivery device.

[0016] The measuring of the filling level may comprise measuring the filling level between discrete time intervals. The discrete time intervals vary over time. The discrete time intervals increase over time.

[0017] The device may be configured to stop measuring the fill level in response to determining that the fill level has not changed within a predetermined time period or a predetermined number of measurements.

[0018] According to a second aspect of the present disclosure, there is provided a system comprising a drug delivery device and the aforementioned apparatus attached to the drug delivery device.The drug delivery device may contain a drug, for example in a container of the drug delivery device.

[0019] The drug delivery device may include a container containing a medicament, the container including a stopper, the stopper having a reflective ring around the circumference of the stopper, wherein the sensor assembly is configured to measure a fill level of the medicament by determining a position of the stopper relative to a longitudinal axis of the container, wherein determining the position of the stopper includes emitting light into the container and detecting light reflected back from the container by the reflective ring.

[0020] According to a third aspect of the present disclosure, a method is provided, comprising: detecting, by a cap sensor of the device, that a cap is at least partially removed from a drug delivery device; waking up a control unit of the device from a sleep state in response to detecting that the cap is at least partially removed from the drug delivery device; and starting to measure a fill level of a medicament in a container of the drug delivery device by a sensor assembly of the device after the control unit is awakened from the sleep state. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Exemplary embodiments of the present invention will be described with reference to the accompanying drawings, in which:

[0022] FIG. 1 is an exploded view of an injection device suitable for use in an embodiment of the present invention;

[0023] 2 is a schematic diagram of an apparatus for measuring a filling level of a medicament in a container according to an embodiment of the present invention, the apparatus being attached to the injection device of FIG. 1 ;

[0024] FIG3A is a diagrammatic representation of an apparatus according to an embodiment of the present invention;

[0025] FIG3B is a schematic diagram of the apparatus of FIG3A mounted on the injection device of FIG1 ;

[0026] FIG4A is a schematic diagram of a cap suitable for use with the apparatus and injection device of FIG3B ;

[0027] FIG4B is an illustration of the cap of FIG4A coupled to the device of FIG3A ;

[0028] FIG5A is a diagrammatic representation of an apparatus according to another embodiment of the present invention and the injection device of FIG1 ;

[0029] FIG5B is an illustration of the device and injection device of FIG5A , wherein the device is mounted on the injection device, and a cap suitable for use with the device and injection device;

[0030] 6 is a diagrammatic representation of an apparatus and the injection device of FIG. 1 and a cap suitable for use with the apparatus and injection device according to another embodiment of the present invention;

[0031] FIG7A is a schematic diagram of the device, injection device and cap of FIG6 , wherein the cap sensor of the device comprises a reed switch;

[0032] FIG7B is a schematic diagram of the apparatus, injection device and cap of FIG6 , wherein the cap sensor of the apparatus comprises a photoelectric sensor;

[0033] 7C is a schematic diagram of the device, injection device and cap of FIG. 6 , wherein the cap sensor of the device comprises a mechanical switch according to the first example;

[0034] 7D is a schematic diagram of the device, injection device and cap of FIG. 6 , wherein the cap sensor of the device comprises a mechanical switch according to a second example;

[0035] FIG7E is a schematic top cross-sectional view of the device, injection device and cap of FIG7C , with the cap removed from the device;

[0036] Fig. 7F is a schematic top cross-sectional view of the device, injection device and cap of Fig. 7E, wherein the cap has been moved toward the device;

[0037] FIG7G is a schematic top cross-sectional view of the device, injection device and cap of FIG7F , wherein the cap has been attached to the device;

[0038] FIG8 is a flow chart of an embodiment of a method according to the present invention;

[0039] FIG9 is a flow chart of an embodiment of a method according to the present invention;

[0040] FIG10A is a partial flow chart of another embodiment of a method according to the present invention;

[0041] FIG10B is a continuation of the flow chart of FIG10A ;

[0042] FIG11A is a schematic diagram of a pharmaceutical container, a stopper, and a reflective ring suitable for use in an embodiment of the present invention;

[0043] FIG11B is a schematic cross-sectional view of the container of FIG11A along line BB';

[0044] 12 is a schematic diagram of the container of FIG. 11A and a fill level sensor configured to measure the fill level of a medicament in the container according to an embodiment of the present invention;

[0045] FIG13 is a graph showing reflected light intensity versus distance along the container of FIG12;

[0046] 14 is a schematic diagram of the fill level sensor of FIG. 12 for providing visual feedback to a user in accordance with aspects of the present invention.

[0047] Reference will now be made in detail to embodiments of the present invention, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout. DETAILED DESCRIPTION

[0048] Embodiments of the present invention provide an apparatus for measuring the fill level of a medicament in a drug delivery device. A cap sensor of the apparatus detects at least partial removal of a cap from the drug delivery device and in response wakes a control unit of the apparatus from a sleep state to start measuring the fill level.

[0049] As described herein, drug delivery devices can be configured to inject medicaments into the patient. For example, delivery can be subcutaneous, intramuscular or intravenous. Such devices can be operated by patients or caregivers (such as nurses or physicians), and can include various types of safety syringes, pen-type syringes or automatic injectors. The device can include a cartridge-based system that requires a sealed ampoule that pierces the container before use. The volume of the medicament delivered with these different devices can be in the range of about 0.5ml to about 2ml.

[0050] In the following, embodiments of the invention will be described with reference to a drug delivery device being an injection device. However, the invention is not limited to this application and may equally be used with other types of drug delivery devices.

[0051] FIG. 1 is an exploded view of an injection device 100 suitable for use with embodiments of the present invention, which injection device may, for example, represent the Solostar injection device of Sanofi. TM (R)Injection pen.

[0052] The injection device 100 has a distal end and a proximal end. The term "distal" refers to a position relatively closer to an injection site, and the term "proximal" refers to a position relatively farther from an injection site.

[0053] The injection device 100 comprises a housing 102 and a cartridge holder 104 for accommodating a medicament container 105. As shown, the housing 102 is substantially cylindrical and has a substantially constant diameter along its longitudinal axis.

[0054] The cartridge holder 104 has a window 107 on one side thereof. When the medication container 105 is contained in the cartridge holder 104, the window 107 allows a user to observe the medication container 105 through the window 107. FIG. 1 shows a stopper 109 of a medication container 105 visible through the window 107. FIG. 1 shows a cartridge holder 104 having one window 107, however the cartridge holder 104 may alternatively have more than one window 107. For example, the cartridge holder 104 may have a first window 107 located on one side of the cartridge holder 104 and a second window 107 located on a second side (or in some cases, the opposite side) of the cartridge holder 104. Thus, a first side of the medication container 105 within the cartridge holder 104 may be seen through the first window 107, while a different second side of the medication container 105 may be seen through the second window 107. Other window 107 configurations may be used.

[0055] The needle 106 can be fixed to the cartridge holder 104 so that the needle 106 is in fluid communication with the medicament container 105. The needle is protected by an inner needle cap 108 and an outer needle cap 110, which in turn is covered by a removable cap 112. When attached to the injection device 100, the cap 112 at least partially covers the cartridge holder 104, and thus covers the medicament container 105. The cap 112 can also be attached to the injection device 100 so that it at least partially covers the cartridge holder 104 without the presence of one or more of the needle 106, the inner needle cap 108 or the outer needle cap 110.

[0056] The cartridge holder 104 may have a cap retaining feature 111 on an outer surface, for example at the proximal end of the cartridge holder 104, adjacent to the housing 102. The cap retaining feature 111 engages with a corresponding coupling feature on the inner surface of the cap 112 to hold the cap 112 in place when attached to the injection device 100. The cap retaining feature 111 may include one or more of a ridge, a groove, a protrusion, a lock, and / or a bump. In some examples, the cap retaining feature is located on the housing 102 of the injection device 100.

[0057] The dose of medicament to be expelled from the injection device 100 can be selected by turning the dose knob 114, and the selected dose is then displayed, for example, in multiples of international units (IU), through the dose window 116. An example of a selected dose displayed in the dose window 116 can be 30 IU, as shown in FIG1. ​​It should be noted that the selected dose can also be displayed differently, such as by an electronic display.

[0058] Turning the dose knob 114 causes a mechanical click to provide audible feedback to the user. The numbers displayed in the dose window 116 are printed on a sleeve (not shown) contained in the housing 102 and mechanically interacting with a stopper 109 (also referred to as a piston) in the medicament container 104. When the needle 106 is inserted into the patient's skin portion and then the injection button 120 is pressed, the dose of medicament displayed in the display window 116 is discharged from the injection device 100. When the needle 106 of the injection device 100 remains in the skin portion for a certain period of time after the injection button 120 is pressed, a high percentage of the dose is actually injected into the patient. The discharge of the medicament dose also causes a mechanical click, however, this is different from the sound produced when the dose knob 114 is used.

[0059] The injection device 100 may be used for several injection procedures until the medicament container 105 is empty or the expiration date of the injection device 100 is reached (eg, 28 days after first use). The injection device 100 may be disposable or reusable.

[0060] Fig. 2 shows a schematic diagram of an apparatus 200 according to aspects of the present invention. The apparatus 200 is used to measure the fill level of a medicament within a drug delivery device, or in other words, to determine the amount of medicament present in a medicament container 105.

[0061] Fig. 2 shows a device 200 as a supplement device, which is configured to be attached to a drug delivery device, such as the injection device 100 of Fig. 1. However, in other examples, the device 200 may be integrally formed with the drug delivery device.

[0062] 2 shows a device 200 coupled to a cartridge holder 104 of an injection device 100 such that the device 200 at least partially obscures the window 107 of the cartridge holder 104. The device 200 may include an attachment means (not shown) for attaching the device 200 to the cartridge holder 104. Examples of attachment means will be discussed later. The attachment means may be configured to releasably or permanently attach the device 200 to the injection device 100.

[0063] Diagram 200 shows the electronics of the device 200. The device 200 includes a control unit 201 for controlling the operation of the various components of the device 200. The control unit 201 may be, for example, a single-core or multi-core microprocessor, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA), etc.

[0064] The device also includes a power source 202, such as a battery or capacitor, for powering the control unit 201 and other electrical components of the device 200. The device 200 may initially be provided to the user without the power source 202. The power source 202 may then be installed by the user into the device 200 prior to use. In some examples, the power source 202 may receive power from an external source via electromagnetic induction.

[0065] The control unit 201 may initially be in a dormant state, also referred to as a sleep state. In this dormant state, the control unit 201 may only perform a limited number of functions among all functions that the control unit 201 may be able to perform, or may not perform any functions. The control unit 201 may be awakened from the dormant state to the awakened state. In the awakened state, the control unit 201 may perform more functions than in the dormant state, or may perform functions different from those in the dormant state. For example, when in the awakened state, the control unit 201 is able to start and control the measurement of the filling level of the medicament in the medicament container 105 of the injection device 100, but not when in the dormant state. Compared to the awakened state, when in the dormant state, the control unit 201 generally consumes less (or zero) power. Therefore, it is advantageous in terms of energy saving to put the control unit 201 in a dormant state before the user needs to use the device 200 and the injection device 100.

[0066] The device 200 includes a cap sensor 203 for detecting that the cap 112 is at least partially removed from the drug delivery device 100 and / or the device 200. The at least partial removal of the cap 112 from the drug delivery device 100 causes a corresponding signal to be sent from the cap sensor 203 to the control unit 201. The control unit 201 can then react accordingly. For example, the sensor 203 detects that the cap 112 is at least partially removed so that the control unit 201 receives a signal that wakes the control unit 201 from a dormant state and converts the control unit 201 to an awake state. In some examples, the sensor 203 detects the attachment / reattachment of the cap 112 so that the control unit 201 receives a signal that converts the control unit 201 from an awake state to a dormant state. For example, the sensor 203 detects the attachment / reattachment of the cap 112 can cause the control unit 201 to stop measuring the fill level of the medication container 105.

[0067] The device 200 also includes a sensor assembly 204, also referred to as a fill level sensor, for measuring the fill level of a medicament in a medicament container 105 of the drug delivery device 100. The sensor assembly 204 may be an optical sensor assembly. FIG. 3 shows a fill level sensor 204 comprising a light source 205 (e.g., an LED array) and a light sensor 206 (e.g., a charge coupled device (CCD)). However, other fill level sensors may also be used. The fill level of the medicament in the medicament container 105 corresponds to the volume of medicament contained in the container 105. In use, the device 200 is attached to the injection device 100 so that the fill level sensor 204 is adjacent to the window 107 of the cartridge holder 104.

[0068] In some examples, the device 200 includes a memory 207. The memory 207 can store instructions executed by the control unit 201 and / or can store measurements made by the sensor assembly 204. The control unit 201 can execute program code (e.g., software or firmware) stored in a program memory (not shown) of the memory 207 and use a main memory (not shown) of the memory 207, for example, to store intermediate results. The main memory can also be used to store a log of the ejections / injections performed and information required to determine a recommendation for the next ejection / injection. The program memory can be, for example, a read-only memory (ROM), and the main memory can be, for example, a random access memory (RAM).

[0069] The device 200 may optionally further comprise a display 208. The display 208 may be an LED display, an LCD display or other type of display known in the art, and may be controlled by the control unit 201 to output information to a user, such as a visual indication of the fill level measured by the fill level sensor 204. The display 208 may also be implemented as a touch screen display, for example for receiving user input.

[0070] The device 200 may further include a communication module 209, which is configured to send and / or receive information to / from another device, which may be an external device such as a smart phone. The communication module 209 is preferably a wireless communication module 209 configured to send and / or receive information to / from another device in a wireless manner. Such transmission may be based on radio transmission or optical transmission, for example. The wireless communication module 209 may use any known wireless protocol (e.g., Bluetooth) to send and / or receive data. However, in some examples, the communication module 209 may be a wired communication module 209. That is, the wired communication module may be configured to send and / or receive data via a wired connection with an external device.

[0071] Figure 3A shows an embodiment of a device 200 of the present invention.As shown in Figure 3B, the device 200 is configured to be slidably received on the cartridge holder 104 of the injection device 100.

[0072] The device 200 comprises a body 301 and an attachment means for attaching the device 200 to the injection device 100. In the example shown in FIG. 3A , the attachment means comprises a collar 302 extending from the body 301, the collar 302 having a hole 303. The collar 302 is configured to receive the drug delivery device 100, in particular the cartridge holder 104 of the drug delivery device 100, through the hole 302. In this way, once the cap 112 has been removed from the drug delivery device 100, the device 200 can be slid on the cartridge holder 104 along the longitudinal axis of the drug delivery device 100 from the distal end towards the proximal end of the drug delivery device 100. FIG. 3A shows the collar 302 as a continuous ring of material, however in some cases the collar 302 may not form a complete ring, but may only partially surround the injection device 100.

[0073] The hole 303 of the collar 302 is sized to have a diameter greater than the diameter of the cartridge holder 104, but smaller than the diameter of the housing 102 of the injection device 100. In this way, the collar 302 of the device 200 can slide along the longitudinal axis of the cartridge holder 104 until the device 200 abuts the housing 102, but no further.

[0074] The attachment means of the device 200 may include a fastener 309 configured to engage with a corresponding fastener (not shown) on the drug delivery device 100 to secure the device 200 to a fixed position of the drug delivery device 100. For example, the fastener 309 may include one or more ridges, grooves, protrusions, locks and / or bumps configured to engage with corresponding ridges, grooves, protrusions, locks and / or bumps on the housing 102 or cartridge holder 104 of the drug delivery device 100. As shown in FIG. 3A , the fastener 309 may be formed on the body 301 of the device 200, but may additionally or alternatively be formed on another portion of the device 200, such as the collar 302.

[0075] The fastener 309 may be configured to engage with a cap retaining feature 111 on the cartridge holder 104 of the drug delivery device 100 to hold the device 200 in place relative to the drug delivery device 100. Additionally or alternatively, the fastener 309 may be provided on the device 200 to engage with a feature of the window 107 of the drug delivery device 100 to hold the device 200 in place relative to the drug delivery device 100. The fastener 309 may secure the device 200 in a fixed rotational and / or translational position relative to the injection device 100. This allows the sensor assembly 204 to be aligned with the window 107 of the cartridge holder 104.

[0076] The body 301 of the device 200 includes a sensor assembly 204 for measuring the fill level of the medicament in the container 105 when the container 105 is held in the cartridge holder 104 of the drug delivery device 100. In the example shown in FIG3A , the body 301 and the sensor assembly 204 extend from the collar 302 in a direction substantially perpendicular to the diameter of the hole 303. Thus, when the device 200 is attached to the drug delivery device 100, the sensor assembly 204 extends substantially along the longitudinal axis of the drug delivery device 100.

[0077] When the device 200 is attached to the drug delivery device 100 , the sensor assembly 204 extends along the outer surface of the cartridge holder 104 , adjacent to the window 107 of the cartridge holder 104 , so that the sensor assembly 204 can detect the medicament fill level within the medicament container 105 when the container 105 is held in the cartridge holder 104 .

[0078] Fig. 3B shows the device 200 of Fig. 3A attached to the injection device 100. The device 200 is positioned such that the sensor assembly 204 covers substantially the entire length of the window 107, thus enabling the fill level of the medicament container 105 to be measured.

[0079] 3A and 3B illustrate the presence of a display 208 on an upper surface of a body 301 of the device 200. The display 208 is located on the body 301 so that it is visible to a user during operation of the device 200. The display 208 can be used to visually convey information to the user, such as a value related to the volume of medication in the medication container 105, or an indication that an injection has been completed. However, the display 208 is an optional feature.

[0080] 4A shows an example of an improved cap 112 suitable for use with a device 200, such as the device 200 shown in FIG. 3A . Here, the cap 112 includes a tubular body 401 configured to receive an injection device 100, in particular a cartridge holder 104 of the injection device 100. The tubular body 401 has a cut-away portion 402 to receive at least a portion of the device 200, such as the body 301, when the cap 112 is attached to the drug delivery device 100.

[0081] FIG. 4B shows a modified cap 112 engaged with the device 200 shown in FIG. 3A . However, other suitable cap configurations may be used, such as those disclosed below. To attach the cap 112 to the drug delivery device 100, the cap 112 is placed on the cartridge holder 104 and slid from the distal end to the proximal end of the drug delivery device 100. The cap 112 is removed from the drug delivery device 100 by sliding the cap 112 in a direction from the proximal end toward the distal end of the drug delivery device 100.

[0082] FIG. 5A shows an alternative embodiment of the device 200 , wherein the device 200 is configured to be attached directly to the cartridge holder 104 of the injection device 100 , in particular the window 107 of the cartridge holder 104 .

[0083] As for the embodiment described with respect to FIG. 3A , the device 200 shown in FIG. 5A comprises a body 301 and attachment means for attaching the device 200 to an injection device 100 .

[0084] FIG. 5A also shows device 200 with an optional display 208, as described above with reference to FIGS. 3A and 3B.

[0085] The device 200 is configured to be attached to the cartridge holder 104 of the injection device 100 within the window 107 of the cartridge holder 104 by means of an attachment means of the device 200. The attachment means comprises one or more fasteners 309a, 309b on the periphery of the body 301, the one or more fasteners 309a, 309b being arranged to engage with one or more corresponding fasteners 310a, 310b arranged on the cartridge holder 104 around the window 107 of the cartridge holder 104.

[0086] The dimensions of the device 200 may correspond to the shape of the window 107 so as to fit within the window 107. FIG5A shows a body 301 of the device 200 having an elongated shape corresponding to the elongated shape of ...

[0087] The device 200 shown in Fig. 5A has a first fastener 309a located at the proximal end of the body 301 and a second fastener 309b located at the distal end of the body 301. The first fastener 309a of the device 200 is configured to engage with a corresponding first fastener 310a located on the cartridge holder 104 proximal to the window 107 of the cartridge holder 104. The second fastener 309b of the device 200 is configured to engage with a corresponding second fastener 310b located on the cartridge holder 104 proximal to the window 107 of the cartridge holder 104.

[0088] One or more fasteners 309a, 309b of the device 200 may include snap features, such as ridges, protrusions, bumps or other such protrusions, while one or more corresponding fasteners 310a, 310b of the cartridge holder 104 may include corresponding grooves, wherein the snap features are configured to engage with the grooves to hold and / or align the device 200 with the injection device 100. In other examples, one or more fasteners 309a, 309b of the device 200 may include grooves, while one or more corresponding fasteners 310a, 310b of the cartridge holder 104 may include snap features.

[0089] The body 301 may also have one or more ridges along its longitudinal perimeter that are configured to engage corresponding walls of the window 107 to assist in aligning the device 200 relative to the window 107 .

[0090] As indicated by the arrow in FIG. 5A , the device 200 may be configured to be attached to the window 107 of the cartridge holder 104 by pushing the device 200 toward and against the window 107 of the cartridge holder 104 until it snaps into an attached state.

[0091] FIG. 5B shows the apparatus of FIG. 5A attached to the cartridge holder 104 of the drug delivery device 100 , ready to measure the fill level.

[0092] 5B also shows a modified cap 112 suitable for use with the device 200 of FIG. 5A or other embodiments of the device 200. Here, the cap 112 includes a tubular body 401 configured to receive the injection device 100, in particular the cartridge holder 104 of the injection device 100. The tubular body 401 has a protruding housing 403 extending along the length of the cap 112 and is configured to pass over the device 200 when the cap 112 is slid onto the drug delivery device 100. However, other suitable cap 112 configurations may be used, such as the cap 112 including the cut-away portion 402 described with reference to FIGS. 4A and 4B.

[0093] FIG6 shows another alternative embodiment of the device 200. In this example, the attachment means of the device 200 comprises a protrusion 309c, such as a pin, located at the proximal end of the body 301 of the device 200, and a fastener 309d located at the distal end of the body 301 of the device 200. The protrusion 301 is configured to be received in a hole 603 located on the drug delivery device 100. FIG6 shows that the hole 603 is located in the face 604 of the housing 102, at the distal end of the housing 102, adjacent to the cartridge holder 104. When received in the hole 603, the protrusion 309c holds the device 200 in a fixed radial position relative to the longitudinal axis of the injection device 100.

[0094] When the device 200 is attached to the drug delivery device 100, the protrusion 309c is inserted into the hole 603 of the drug delivery device 100, as shown by the dashed arrow in Figure 6. The distal end of the device 200 is then pivoted toward the cartridge holder 104 until the fastener 309d engages with the cartridge holder 104 to secure the device 200 to the drug delivery device 100. In particular, the fastener 309d engages with the corresponding fastener 310d on the cartridge holder 104 to secure the device 200. For example, as shown in Figure 6, the corresponding fastener 310d can be located on the wall of the window 107 of the cartridge holder 104. In some examples, in addition to or as an alternative to the fastener 602 located at the distal end of the device 200, the fastener 310d can be located along the outer surface of the cartridge holder 104 of the device 200.

[0095] 7A-D illustrate various exemplary embodiments of a cap sensor 203 according to the present invention, although other suitable types of cap sensors may be used.

[0096] FIG. 7A shows a cap sensor 203 including a reed switch 701. In such an embodiment, the cap 112 includes a magnet 702. A reed switch 704 is located in the device 200 and the magnet 702 is located in the cap 112 such that when the cap 112 is attached to the drug delivery device 100, the magnet 702 interacts with the reed switch 701. When the cap 112 is at least partially removed from the drug delivery device 100, the magnet 702 is removed from the vicinity of the reed switch 701, and this is detected by the reed switch 701 and a corresponding signal is sent to the control unit 201. Thus, when the cap 112 is at least partially removed from the drug delivery device 100, this is detected by the cap sensor 701 and in response, the control unit 201 wakes up from a sleep state. Similarly, the reed switch 701 also detects the attachment / reattachment of the cap 112.

[0097] FIG7B shows a cap sensor 703, which includes a photosensor 703, such as a photodiode. The photosensor 703 is arranged to detect changes in ambient light when the cap 112 is removed from the injection device 100. The photosensor 703 is located on the body 301 of the device 200 so that when the cap 112 is removed from the drug delivery device 100, it receives ambient light, but when the cap 112 is attached to the drug delivery device 100, it receives less ambient light (or no ambient light). When the cap 112 is at least partially removed from the drug delivery device 100, this is detected by the photosensor 703 as an increase in the amount of ambient light detected by the photosensor 703. In response, the control unit 201 is awakened from the sleep state. Similarly, the attachment / reattachment of the cap 112 is also detected by the photosensor 703.

[0098] 7C and 7D illustrate an embodiment in which the cap sensor includes mechanical switches 704 , 705 .

[0099] In FIG. 7C , the mechanical switch comprises a slide switch 704 located on the surface of the device 200. The slide switch 704 is movable between a first longitudinal position and a second longitudinal position relative to the longitudinal axis of the injection device 100. The cap 112 comprises an engagement feature 710, such as a protrusion on the inner surface of the cap 112. The engagement feature 710 is configured to engage with the slide switch 704 so that when the cap 112 is attached to the drug delivery device 100, the slide switch 704 is in the first longitudinal position, and when the cap 112 is at least partially removed from the drug delivery device 100, the engagement feature 710 moves the slide switch 704 to the second longitudinal position. This change from the first longitudinal position to the second longitudinal position is used to determine that the cap 112 is at least partially removed, and in response, the control unit 201 is awakened from the sleep state. Similarly, the slide switch 704 also detects the attachment / reattachment of the cap 112.

[0100] In FIG. 7D , the mechanical switch includes a button 705, which is in a first (pressed) state when the cap 112 is attached to the drug delivery device 100, and is in a second (released) state when the cap 112 is at least partially removed from the drug delivery device 100. The button is pushed into the first state by the inner surface of the cap 112. The button 705 can be biased in the second state, for example, by an elastic member such as a spring. The change from the first state to the second state causes the circuit in the mechanical switch to be connected (or disconnected in some cases), which is used to determine that the cap 112 is at least partially removed. In response, the control unit 201 is awakened from the dormant state. Similarly, the attachment / reattachment of the cap 112 is also detected by the button 705.

[0101] FIG. 7E is a schematic top view of an embodiment of the cap 112 and the slide switch 704 shown in FIG. 7C , showing how the cap 112 interacts with the slide switch 704. FIG. 7E shows an initial position of the cap 112 relative to the device 200, wherein the cap 112 is at least partially removed from the device 200. For clarity, the device 200 and the injection device 100 are not shown as a whole. The cap 112 is shown in cross section, while the device 200 is shown in a top view. The cap 112 has an engagement feature 710 disposed on an inner surface of the cap 112. The engagement feature 710 is configured to engage with the slide switch 704 to move the slide switch 704 between an open position and a closed position when the cap 112 is attached to / detached from the device 200.

[0102] In the example shown in FIG. 7E , the engagement feature 710 includes a first resilient protrusion 712 and a second resilient protrusion 714. The first resilient protrusion 712 and the second resilient protrusion 714 may be flexible arms. The first resilient protrusion 712 and the second resilient protrusion 714 are biased toward each other. To attach or reattach the cap 112 to the device 200, the user places the cap 112 on the end of the device 200 and pushes the cap 112 in the direction indicated by the arrow in FIG. 7E .

[0103] FIG. 7F shows the cap 112 and the device 200 of FIG. 7E after the cap 112 has moved a certain distance toward the device 200. When the cap 112 is pushed toward the device 200 by the user, the first elastic protrusion 712 and the second elastic protrusion 714 are separated by the slide switch 704. The slide switch 704 preferably includes a circular or rounded protrusion to facilitate the separation of the first elastic protrusion 712 and the second elastic protrusion 714. After the first elastic protrusion 712 and the second elastic protrusion 714 are pushed apart, the engagement element 710 engages with the slide switch 704 so that the slide switch 704 (or its protrusion) is retained between the first elastic protrusion 712 and the second elastic protrusion 714, as shown in FIG. 7F.

[0104] 7G shows the cap 112 and device 200 of FIG. 7F after the cap 112 has been moved further toward the device 200 so that the cap 112 is now fully attached to the device 200. The movement of the cap 112 toward the device 200 has caused the engagement element 710 to move the slide switch 704 from the first position to the second position. If the control unit 201 detects that the slide switch 704 is in the first position, it is determined that the cap 112 is at least partially detached from the device 200. If the control unit 201 detects that the slide switch 704 is in the second position, it is determined that the cap 112 is attached to the device 200.

[0105] When the cap 112 is removed from the device 200, the stages shown in Figures 7E to 7G are reversed. That is, the slide switch 704 is initially in the second position and is held between the first elastic protrusion 712 and the second elastic protrusion 714. As the cap 112 is removed from the device 200, the engagement element 710 moves the slide switch 704 back to the first position from the second position. This is due to the elasticity of the first elastic protrusion 712 and the second elastic protrusion 714 that the slide switch 704 is held between the first elastic protrusion 712 and the second elastic protrusion 714 when the cap 112 is removed. Finally, once the cap 112 is further removed from the device 200 and the slide switch 704 cannot move further, the engagement element 710 releases the slide switch 704, as shown in Figure 7E.

[0106] FIG. 8 is a flow chart illustrating a method according to one aspect of the present invention.

[0107] Before performing an injection, the user removes the cap 112 from the drug delivery device 100. In step 810, the cap sensor 203 detects that the cap 112 is at least partially removed from the drug delivery device 100. By detecting the removal of the cap 112, wake-up of the device 200 is initiated.

[0108] In step 820, and in response to detecting that the cap 112 is at least partially removed from the drug delivery device 100, the control unit 201 is awakened from the dormant state to the awake state. When in the dormant state, the control unit 201 may not be able to initiate a measurement of the fill level using the sensor assembly 204, but when in the awake state, may initiate a measurement of the fill level.

[0109] In step 830, and after the control unit 201 is awakened from the sleep state, measurement of the fill level of the medicament in the container 105 of the drug delivery device 100 is started. The control unit 201 may cause the sensor assembly 204 to start measuring the fill level of the medicament contained in the container 105 of the drug delivery device 100. The measurement of the fill level may be automatically initiated in response to the control unit 201 being awakened from the sleep state, for example, immediately after being awakened or after a predetermined time period after being awakened. In other examples, the measurement of the fill level by the sensor assembly 204 may be initiated in response to a signal received by the wireless communication module 209 from an external device such as a smartphone, wherein the signal is received after the control unit 201 is awakened.

[0110] The sensor assembly 204 can make a single measurement of the filling level, or can make continuous measurements of the filling level. In other examples, the sensor assembly 204 can make multiple discrete measurements separated by time intervals, such as once per second. Compared with making continuous measurements, making a discrete series of measurements can improve the energy efficiency of the device 200. The time interval between each measurement may be different. For example, the length of each time interval in the time interval sequence can increase over time, so that the measurement starts with a short time interval, such as a fraction of a second (1 / 10, 1 / 10, ...) or a few seconds (1, 2, 4, ...) and ends at intervals of many seconds or minutes, thereby reducing energy consumption. When it is determined that two (or three or more) consecutive measurements provide the same value, or in some examples provide the same value within a confidence level (e.g., 5%), the measurement can be ended. The control unit 201 is then placed in a sleep mode.

[0111] The measurement may continue until the cap sensor 203 determines that the cap 112 has been reattached to the drug delivery device 100. In some examples, the measurement may continue until the control unit 201 has determined that a predetermined time period has elapsed, such as a time period from the start of the fill level measurement or from the wireless communication module 209 receiving a signal from an external device such as a smartphone.

[0112] In other examples, such as the example process of FIG. 9 , the measurement may continue until the control unit 201 (or an external device such as a smartphone) determines that the sensor assembly 204 has measured a predetermined fill level (value) and thus the end of the injection has been reached. In some examples, the measurement may continue until the wireless communication module 209 receives a corresponding signal from an external device such as a smartphone.

[0113] FIG. 9 is an exemplary flow chart of a process performed by the control unit 201 according to certain embodiments.

[0114] In step 840, it is determined whether the device 200 is in a dormant state. If the device is not in a dormant state (i.e., it has been awakened), the device initiates a measurement of the fill level (step 842). On the other hand, if it is determined in step 840 that the device 200 is in a dormant state, then in step 844, the device 200 is awakened from the dormant state. This step may be performed in response to detecting that the cap 112 is removed from the device 200. Once the device 200 is awakened, the device 200 begins a measurement of the fill level using the fill level sensor assembly 204 (step 842).

[0115] In step 846, the fill level is continuously measured by the sensor assembly 204 for a period of time, such as 10 seconds. During this period of time, or after this period of time, it is determined in step 848 whether the measurement of the fill level has changed. If the measurement of the fill level has not changed, or in some examples, if the measurement of the fill level has not changed by more than a predetermined threshold, the device 200 stops continuously measuring the fill level and begins measuring the fill level at discrete time intervals (step 850). For example, a measurement may be made once per second. In step 852, it is again determined whether the measurement of the fill level has changed, and in some examples, the amount of change exceeds a threshold amount. Step 852 may be performed within a predetermined period of time after the start of step 850, or after a predetermined number of discrete measurements have been made during step 850. If it is determined in step 852 that the measurement of the fill level has not changed, or in some examples, if the measurement of the fill level has not changed by more than a predetermined threshold, the device 200 may be placed in a dormant state, and the measurement of the fill level may stop. The method of FIG. 9 may then start again from step 840.

[0116] If it is determined at step 848 or step 852 that the fill level measurement has changed, or in some examples, if the fill level measurement has changed by more than a predetermined threshold, the device 200, the method proceeds to step 854, where it is determined whether a desired value for the fill level has been reached. The desired value for the fill level corresponds to a particular measurement of the fill level that indicates that the injection device 100 has expelled a desired dose of the drug. If so, the device 200 may process the fill level data at step 858, and in some examples output an audible, visual, or tactile alert to the user indicating that the injection is complete. In some examples, processing the data may include recording one or more fill level measurements in the memory 207 of the device 200, and / or transmitting one or more measurements or an indication of the completion of the injection to a separate external device, such as a computer or smartphone, for example, using the communication module 209. The device 200 may then be placed in a sleep state, and the method returns to step 840.

[0117] If it has been determined at step 854 that the expected value of the filling measurement result has not been reached, the device may start measuring the filling level at discrete time intervals that are smaller than the discrete time interval of step 850 (eg every 0.1 seconds). The method then returns to step 848.

[0118] Figures 10A and 10B are flow charts illustrating another method of determining a fill level according to an exemplary embodiment. Figure 10B is a continuation of Figure 10A.

[0119] 10A and 10B illustrate certain steps of the method performed on a smartphone, although another external computing device may be used instead.

[0120] In step 900, a medication injection is due. In optional step 904, a reminder function is activated on the smartphone, indicating that the injection is due. In step 908, an application is opened on the smartphone. The application may be opened automatically in response to the reminder function being activated, or may be opened by the user.

[0121] In step 912, a target dose is determined. The target dose represents the amount of medication that the user should expel from the drug delivery device 100. The user can manually enter the target dose into the smartphone, or the target dose can be calculated by the smartphone based on one or more parameters. The target dose can be calculated based on parameters received by the smartphone from different external devices, such as a blood glucose monitor or a server in communication with the smartphone.

[0122] In step 916, the user confirms the target dose to be administered. This can be accomplished by the user providing input to the smartphone, such as selecting a graphical user interface (GUI) icon on a smartphone touch screen, or actuating a button. Other inputs known in the art may be used. In some examples, the target dose may not require confirmation.

[0123] Once the target dose is determined and optionally confirmed, the smartphone connects to the device 200 (step 920), and if this has not already been done, wirelessly transmits data indicative of the target dose to the device 200 (step 924). The device receives the data via the communication module 209 of the device 200 (step 936), and may optionally display a visual indication of the target dose on the display 208 of the device 200, making it visible to the user (step 940).

[0124] At some stage before the target dose is transmitted from the smartphone to the device, the user removes the cap 112 from the injection device 200 (step 928). In response, the control unit 201 of the device 200 wakes up from the sleep state to the awake state (step 932), as discussed in relation to Figures 8 and 9. Thus, the device 200 is now ready to receive target dose data from the smartphone.

[0125] At step 944, measurement of the fill level of the medicament in the container 105 of the injection device 100 is started. This may be in response to the control unit 201 being awakened in step 932, or in response to the communication module 209 receiving a signal, such as target dose data, from the smartphone. Then, as previously described, the fill level measurement is performed by the control unit 201 and the sensing device 204 (step 956).

[0126] In step 948, the user dials a dose for the drug delivery device 100 using the dose knob 114. While dialing a dose, the user will be able to see an indication of the currently dialed dose on the sleeve of the drug delivery device 100 through the dose window 116. The user may continue to dial doses until the dialed dose equals the target dose previously indicated on the smartphone and optionally displayed on the display 208 of the device 200.

[0127] Preferably, the display 208 of the device 200 and the dose window 116 of the drug delivery device 100 are positioned and oriented relative to each other so that a user can view the display 208 and the dose window 116 simultaneously, or can view between the two without difficulty. In this way, the user can easily determine when the dialed dose is equal to the target dose indicated on the display 208 of the device 200. Such a suitable configuration is shown in Figures 3B, 5B, 6, and 7A to 7D.

[0128] After the target dose has been dialed, the user initiates injection of the drug from the drug delivery device 100 by pressing the injection button 120 (step 952 ).

[0129] During the injection, the sensor assembly 204 of the device 200 measures the fill level of the medicament (step 956). The data corresponding to each fill level measurement is stored in the memory 207 of the device 200 (step 960).

[0130] In step 964, it is determined by the control unit 201 of the device 200 whether the target dose has been injected, thereby indicating that the injection is complete. Whether the target dose has been injected is determined based on one or more fill level measurements. If the target dose has not been injected, the device continues to measure fill levels and store measurements (steps 956 and 960) until it is determined that the target dose has been injected.

[0131] To determine whether the target dose has been injected, the control unit 201 may determine the difference between the first fill level measurement and the subsequent second fill level measurement. If the difference is greater than or equal to a predetermined value, this may indicate that the target dose has been injected. The predetermined value will be pre-calculated by the smartphone or device 200 based on the target dose.

[0132] In step 968, the user completes the injection and then waits for the dwell time (step 984). Once the device 200 determines that the target dose has been injected, in step 972, the device 200 sends a signal to the smartphone indicating that the injection is complete. At this point, the control unit 201 can stop further measurements of the fill level.

[0133] In response to receiving the signal that the injection is complete, the smartphone may store information related to the injection in a memory of the smartphone (step 976). For example, the smartphone may store one or more of the target dose, the injected dose, an indication that the injection is complete, the time when the injection started, and / or the time when the injection is complete. The smartphone may also confirm to the user that the injection is complete (step 980), for example by outputting an audible, visual, and / or tactile alarm. In step 996, the user removes the needle of the injection device 100 from the patient's skin. This may be in response to the smartphone's confirmation output in step 980.

[0134] In some examples, the device 200 transmits data representing one or more measurements of the fill level to the smartphone. For example, the device 200 may transmit data representing the measured fill level to the smartphone after each measurement of the fill level by the fill level sensor, or after a specific time interval. In this case, the smartphone is constantly updated with the fill level of the medicament. This may be communicated to the user via a visual indication on the smartphone display so that the user can see how the injection is progressing. In such an example, in addition to or in lieu of such a determination by the device, the smartphone may determine when the injection is complete.

[0135] In response to determining that the injection is complete, the smartphone may send a signal to the device 200 (step 988). In response to receiving the signal, the control unit 201 of the device 200 may enter a sleep state (step 992). In other examples, the device 200 may automatically transition the control unit 201 to a sleep state after determining that the injection is complete, or after a predetermined time period has passed.

[0136] FIG. 11A illustrates an exemplary medication container 105 , such as a cartridge, according to aspects of the present invention.

[0137] The container 105 comprises a substantially cylindrical body 1010 and a stopper 109, the body defining a reservoir 1020 for containing the drug, the stopper also being referred to as a piston, plug or plunger. The stopper 109 can be longitudinally moved from the proximal end to the distal end of the container 105 within the cylindrical body 1010 to dispense the medicament from the container 105. The medicament is dispensed through a hole 1030 of the container 105, which can initially be sealed by a septum 1040. The septum 1040 can be pierced by a needle 109 before injection.

[0138] The container 105 can be made of plastic (such as cyclic olefin copolymer) or glass. Other suitable materials can also be used.

[0139] At least a portion of the container 105 is transparent so that a user can see from the outside the fill level of the medicament in the container 105. FIG11A shows a container 105 that includes an elongated transparent window 1050 extending from near the proximal end of the container 105 to the distal end of the container 105 in the cylindrical body 1010. The window 1050 is an optically transparent area of ​​the container 105. In other examples, substantially the entire container 105 may be transparent, or more than one window 1050 may be present.

[0140] Figure 11B shows a cross section of the cartridge of Figure 11A along line BB'. A portion of the inner surface 1051 and a portion of the outer surface 1052 of the window 1050 are substantially flat and parallel to each other. As described with reference to Figure 12, this can improve the accuracy of the fill level determination.

[0141] 11A also shows an exemplary stopper 109 that is generally positioned within the container 105. The stopper 109 has a reflective indicia around its circumference, such as a reflective ring 1091. When the stopper 109 is positioned within the container 105, the reflective ring 1091 is visible from outside the container 105 through the elongated transparent window 1050. The position of the reflective ring 1091 relative to the elongated transparent window 1050 can be used to determine the fill level of the medicament in the container 105. In some examples, the reflective ring 1091 only partially surrounds the stopper 109.

[0142] Initially, when the container 105 is filled with the medicament, the reflective ring 1091 will be located near the proximal end of the container 105. As the stopper 108 moves from the proximal end to the distal end of the container 105, thereby dispensing the medicament from the container 105, the reflective ring 1091 also moves from the proximal end to the distal end of the container 105. Therefore, the position of the reflective ring 1091 relative to the container 105 indicates the fill level of the medicament in the container 105.

[0143] FIG. 12 shows an arrangement for measuring the fill level in a container 105 according to aspects of the present invention. In this arrangement, a sensor assembly 204 of the device 200 comprises a light source 205 and a light sensor 206. The light source 205 comprises a plurality of LEDs 205a arranged in a straight line along a plane so that when the device 200 is attached to the injection device 100, they are parallel to the longitudinal axis of the container 105 indicated by the dashed arrow adjacent to the elongated transparent window 1050. However, in some examples, the light source 205 may be a single LED, or one or more other types of light sources. The light sensor 206 of the sensor assembly 204 comprises a charge coupled device (CCD) arranged in a plane parallel to the longitudinal axis of the container 105, adjacent to the elongated transparent window 1050 and parallel to the plane of the LEDs 205a. However, in some examples, different forms of light sensors 206 may be used. The light source 205 and the light sensor 206 are preferably adjacent to each other, which allows a compact design of the device 200.

[0144] The light sensor 206 is configured to detect light from the light source 205 that has been reflected by the reflective ring 1091. In operation, light emitted from one or more LEDs 205a of the light source 205 is transmitted through the elongated transparent window 1050 and enters the container 105. At least a portion of the light is reflected by the reflective ring 1091 of the stopper 109, returning through the elongated transparent window 1050. The light sensor 206 detects the reflected light. In particular, the position of the reflected light relative to the container 105 is detected by the light sensor 205. The position of the reflected light, or more precisely, the peak intensity of the reflected light relative to the position of the container 105 indicates the position of the stopper 109 in the container 105, and therefore indicates the filling level of the medicament M in the container 105. The measurement of the filling level can be determined by the control unit 201 based on one or more signals output from the sensor assembly 204.

[0145] 13 is a graph showing the variation of the light intensity I determined by the light sensor 206 as a function of the position S along the longitudinal axis of the container 105 of FIG. 12 for a stopper 109 located at a position X along the longitudinal axis of said container 105. The reflective properties of the reflective ring 1091 mean that the peaks of the light intensity correspond to the position of the stopper 109 relative to the container 105. The position of the stopper 109 can be used to infer the fill level of the medicament in the container 105, for example using a known volume of the container 105.

[0146] 14 shows how the sensor assembly 204 can be used to provide feedback to the user about the fill level of the medication in the container 105. The light emitted by the light source 205, such as LED 205a, is visible to the user outside the device 100. In this case, at least a portion of the medication container 105 is transparent, and at least a portion of the cartridge holder 104 opposite the window 107 is transparent, and the device 200 is attached to the window 107. Thus, the light from the one or more LEDs 205a is transmitted through the cartridge 105 to the outside of the device 100.

[0147] In some examples, when the control unit 201 and the sensor assembly 204 determine that the medication container 105 is full or substantially full of medication, the one or more LEDs 205a may emit light of a first color (e.g., green). When the control unit 201 and the sensor assembly 204 determine that the medication container 105 is partially filled with medication, the one or more LEDs 205a may emit light of a second color (e.g., yellow or orange). When the control unit 201 and the sensor assembly 204 determine that the medication container 105 is empty or substantially free of medication, the one or more LEDs 205a may emit light of a third color (e.g., red).

[0148] In some examples, the number of LEDs 205a currently illuminated can correspond to the fill level. For example, when the container 105 is full or substantially full of medication, multiple LEDs 205a can be illuminated; when the container 105 is partially filled with medication, fewer LEDs 205a can be illuminated; then when the container 105 is empty or substantially free of medication, even fewer LEDs 205a can be illuminated (or even no LEDs 205a can be illuminated).

[0149] Although the claims are expressed as specific combinations of features in this application, it should be understood that the scope of the present disclosure also includes any novel features or any novel combination of features disclosed herein explicitly or implicitly, or any generalization thereof, whether or not it relates to the same invention currently claimed in any claim, and whether or not it alleviates any or all technical problems that are the same as the present invention. The applicant hereby gives notice that new claims may be made to these features and / or combinations of features during the course of this application or any further application derived therefrom.

[0150] Although several embodiments have been shown and described, it will be appreciated by those skilled in the art that changes may be made to these embodiments without departing from the principles of the invention, the scope of which is defined by the claims.

[0151] The terms "drug" or "medicament" are used synonymously herein and describe a pharmaceutical preparation containing one or more active pharmaceutical ingredients or a pharmaceutically acceptable salt or solvate thereof and optionally a pharmaceutically acceptable carrier. In the broadest sense, an active pharmaceutical ingredient ("API") is a chemical structure that has a biological effect on humans or animals. In pharmacology, a drug or medicament is used to treat, cure, prevent, or diagnose a disease or to otherwise enhance physical or mental health. A drug or medicament may be used for a limited time or periodically for a chronic disease.

[0152] As described below, a drug or medicament may include at least one API or a combination thereof in various types of formulations for treating one or more diseases. Examples of APIs may include small molecules (having a molecular weight of 500 Da or less); polypeptides, peptides, and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes); carbohydrates and polysaccharides; and nucleic acids, i.e., double-stranded or single-stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems (such as vectors, plasmids, or liposomes). Mixtures of one or more drugs are also contemplated.

[0153] The drug or medicament can be contained in a primary package or "drug container" suitable for use with a drug delivery device. The drug container can be, for example, a cartridge, a syringe, a reservoir or other solid or flexible vessel, which is configured to provide a suitable chamber for storing (e.g., short-term or long-term storage) one or more drugs. For example, in some cases, the chamber can be designed to store the drug for at least one day (e.g., 1 day to at least 30 days). In some cases, the chamber can be designed to store the drug for about 1 month to about 2 years. It can be stored at room temperature (e.g., about 20 ° C) or refrigerated temperature (e.g., from about -4 ° C to about 4 ° C). In some cases, the drug container can be or can include a dual-chamber cartridge, which is configured to store two or more components (e.g., API and diluent, or two different drugs) of a drug preparation to be administered separately, one of which is stored in each chamber. In such cases, the two chambers of the dual-chamber cartridge can be configured to allow mixing between two or more components before and / or during distribution to the human or animal body. For example, the two chambers may be configured so that they are in fluid communication with each other (e.g., by means of a conduit between the two chambers) and allow the user to mix the two components if desired prior to dispensing. Alternatively or additionally, the two chambers may be configured to allow mixing when the components are dispensed into a human or animal body.

[0154] The medicine or medicament contained in the drug delivery device as described herein can be used to treat and / or prevent many different types of medical disorders. The example of obstacle includes, for example, diabetes or complications associated with diabetes (such as diabetic retinopathy), thromboembolic disorders (such as deep vein or pulmonary thromboembolism). Another example of obstacle is acute coronary syndrome (ACS), angina pectoris, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and / or rheumatoid arthritis. The example of API and medicine is those as described in the following manual: such as Rote Liste 2014 (for example, but not limited to, main group (main group) 12 (antidiabetic drugs) or 86 (tumor drugs)) and Merck Index, the 15th edition.

[0155] Examples of APIs for treating and / or preventing type 1 or type 2 diabetes or complications associated with type 1 or type 2 diabetes include insulin (e.g., human insulin, or human insulin analogs or derivatives); glucagon-like peptide (GLP-1), GLP-1 analogs or GLP-1 receptor agonists, or analogs or derivatives thereof; dipeptidyl peptidase-4 (DPP4) inhibitors, or pharmaceutically acceptable salts or solvates thereof; or any mixture thereof. As used herein, the terms "analogs" and "derivatives" refer to polypeptides having a molecular structure that can be formally derived from the structure of a naturally occurring peptide (e.g., the structure of human insulin) by deleting and / or exchanging at least one amino acid residue present in a naturally occurring peptide and / or by adding at least one amino acid residue. The added and / or exchanged amino acid residues can be codable amino acid residues or other naturally occurring residues or purely synthetic amino acid residues. Insulin analogs are also referred to as "insulin receptor ligands." In particular, the term "derivative" refers to a polypeptide having a molecular structure that is formally derived from the structure of a naturally occurring peptide (e.g., the structure of human insulin), wherein one or more organic substituents (e.g., fatty acids) are bound to one or more amino acids. Optionally, one or more amino acids present in the naturally occurring peptide may have been deleted and / or replaced by other amino acids (including non-encodable amino acids), or amino acids (including non-encodable amino acids) have been added to the naturally occurring peptide.

[0156] Examples of insulin analogs are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulin glulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28) human insulin (insulin aspart); human insulin in which the proline at position B28 is replaced by Asp, Lys, Leu, Val or Ala and in which the Lys at position B29 may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.

[0157] Examples of insulin derivatives are, for example, B29-N-myristoyl-des(B30) human insulin, Lys(B29)(N-tetradecanoyl)-des(B30) human insulin (insulin detemir, ); B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoylLysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-γ-glutamyl)-des(B30) human insulin, B29-N-ω-carboxypentadecanoyl-γ-L-glutamyl-des(B30) human insulin (insulindegludec, ); B29-N-(N-lithocholyl-γ-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.

[0158] Examples of GLP-1, GLP-1 analogs and GLP-1 receptor agonists are e.g. lixisenatide Exendin-4 Liraglutide (a 39-amino acid peptide produced by the salivary glands of the Gila monster) Semaglutide, Taspoglutide, Albiglutide Dulaglutide rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide / HM-11260C, CM-3, GLP-1 Eligen, ORMD-0901, NN-9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, TT-401, BHM-034, MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, Exenatide-XTEN, and Glucagon-Xten.

[0159] Examples of oligonucleotides are: Mipomersen sodium It is a cholesterol-reducing antisense therapeutic used to treat familial hypercholesterolemia.

[0160] Examples of DPP4 inhibitors are Vildagliptin, Sitagliptin, Denagliptin, Saxagliptin, Berberine.

[0161] Examples of hormones include pituitary hormones or hypothalamic hormones or regulatory activity peptides and their antagonists, such as gonadotropins (follicle-stimulating hormone, luteinizing hormone, chorionic gonadotropin, tocopherol), somatropine (growth hormone), desmopressin, terlipressin, gonadorelin, triptorelin, leuprorelin, buserelin, nafarelin and goserelin.

[0162] Examples of polysaccharides include glucosaminoglycanes, hyaluronic acid, heparin, low molecular weight heparin or ultra low molecular weight heparin or derivatives thereof, or sulfated polysaccharides (e.g., polysulfated forms of the above polysaccharides), and / or pharmaceutically acceptable salts thereof. An example of a pharmaceutically acceptable salt of polysulfated low molecular weight heparin is enoxaparin sodium. An example of a hyaluronic acid derivative is Hylan G-F20 It is a sodium hyaluronate.

[0163] As used herein, the term "antibody" refers to an immunoglobulin molecule or an antigen binding portion thereof. Examples of antigen binding portions of immunoglobulin molecules include F (ab) and F (ab') 2 fragments, which retain the ability to bind antigens. The antibody can be a polyclonal antibody, a monoclonal antibody, a recombinant antibody, a chimeric antibody, a deimmunized or humanized antibody, a fully human antibody, a non-human (e.g., mouse) antibody, or a single-chain antibody. In some embodiments, the antibody has effector functions and can fix complement. In some embodiments, the antibody has reduced or no ability to bind to Fc receptors. For example, the antibody can be an isotype or subtype, an antibody fragment or a mutant, and the antibody does not support binding to Fc receptors, for example, it has a mutagenic or missing Fc receptor binding region. The term antibody also includes antigen binding molecules based on tetravalent bispecific tandem immunoglobulins (TBTI) and / or dual variable region antibody-like binding proteins with cross-binding region orientation (CODV).

[0164] The term "fragment" or "antibody fragment" refers to a polypeptide derived from an antibody polypeptide molecule (e.g., an antibody heavy chain and / or light chain polypeptide), which does not include a full-length antibody polypeptide, but still includes at least a portion of a full-length antibody polypeptide capable of binding to an antigen. An antibody fragment may include a cleavage portion of a full-length antibody polypeptide, although the term is not limited to such a cleaved fragment. Antibody fragments that can be used in the present invention include, for example, Fab fragments, F(ab')2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments (e.g., bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., double-chain antibodies, three-chain antibodies, four-chain antibodies)), monovalent or multivalent antibody fragments (e.g., bivalent, trivalent, tetravalent and multivalent antibodies), mini antibodies, chelated recombinant antibodies, three antibodies or double antibodies, intracellular antibodies, nano antibodies, small modular immunopharmaceuticals (SMIP), binding domain immunoglobulin fusion proteins, camelized antibodies and antibodies containing VHH. Other examples of antigen-binding antibody fragments are known in the art.

[0165] The term "complementarity determining region" or "CDR" refers to short polypeptide sequences within the variable region of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term "framework region" refers to amino acid sequences within the variable region of both heavy and light chain polypeptides that are not CDR sequences and are primarily responsible for maintaining the correct positioning of the CDR sequences to allow antigen binding. Although the framework region itself is typically not directly involved in antigen binding, as known in the art, certain residues within the framework region of certain antibodies may be directly involved in antigen binding or may affect the ability of one or more amino acids in the CDR to interact with the antigen.

[0166] Examples of antibodies are anti-PCSK-9 mAb (eg, Alirocumab), anti-IL-6 mAb (eg, Sarilumab), and anti-IL-4 mAb (eg, Dupilumab).

[0167] Pharmaceutically acceptable salts of any API described herein are also contemplated for use in a drug or medicament in a drug delivery device. Pharmaceutically acceptable salts are, for example, acid addition salts and basic salts.

[0168] Those skilled in the art will appreciate that modifications (additions and / or removals) may be made to the various components of the API, formulations, apparatus, methods, systems and embodiments described herein without departing from the overall scope and spirit of the invention, and that the invention encompasses such modifications and any and all equivalents thereof.

Claims

1. A device for measuring the fill level of a medicament in a container of a drug delivery device, include: Control unit; a sensor assembly configured to measure a fill level of a medicament within a reservoir of a drug delivery device; and a cap sensor configured to detect at least partial removal of a cap from the drug delivery device; wherein the control unit is configured to be awakened from a dormant state in response to the cap sensor detecting that the cap has been at least partially removed from the drug delivery device, wherein the sensor assembly is configured to start measuring the fill level after the control unit is awakened from the sleep state, and The measuring of the filling level comprises measuring the filling level between discrete time intervals, the discrete time intervals varying with time. 2 . The apparatus according to claim 1 , wherein the measuring of the fill level is initiated in response to the cap sensor detecting that the cap has been at least partially removed from the drug delivery device. 3 . The device according to claim 1 , wherein the device comprises a wireless communication module, and wherein the measurement of the fill level is started in response to the wireless communication module receiving a signal.

4. The device of claim 1, wherein the device is a supplemental device attachable to the drug delivery device.

5. The apparatus of claim 4, wherein the apparatus is attachable to a cartridge holder of the drug delivery device, the cartridge holder being configured to accommodate the container.

6. The apparatus of claim 5, wherein the apparatus comprises a collar, wherein the collar is configured to receive a cartridge holder of the drug delivery device through a hole of the collar.

7. The apparatus of claim 5, wherein the sensor assembly is configured to measure the fill level through a window in a cartridge holder of the drug delivery device.

8. The apparatus of claim 1, wherein the apparatus comprises a wireless communication module and is configured to transmit a signal from the wireless communication module to an external device, the signal comprising data representative of one or more fill level measurements made by the sensor assembly.

9. The apparatus according to claim 8, wherein the measuring of the filling level is stopped in response to the wireless communication module of the apparatus receiving a signal from the external device.

10. The apparatus of claim 1, wherein the measuring of the fill level is stopped in response to the cap sensor detecting that the cap is reattached to the drug delivery device.

11. An apparatus according to any preceding claim, wherein the apparatus is configured to stop measuring the fill level in response to determining that the fill level has not changed within a predetermined time period or a predetermined number of measurements.

12. A system comprising a drug delivery device and a device attached to the drug delivery device, wherein the device is a device according to any one of claims 1 to 11.

13. A system according to claim 12, wherein the drug delivery device includes a container containing a medicament, the container including a stopper, the stopper having a reflective ring around the circumference of the stopper, wherein the sensor assembly is configured to measure the fill level of the medicament by determining the position of the stopper relative to the longitudinal axis of the container, wherein determining the position of the stopper includes emitting light into the container and detecting light reflected back from the container by the reflective ring.

14. A method for measuring the fill level of a medicament in a container of a drug delivery device, wherein include: detecting, by a cap sensor of the device, at least partial removal of the cap from the drug delivery device; waking up a control unit of the device from a dormant state in response to detecting that the cap is at least partially removed from the drug delivery device; as well as After the control unit is awakened from the sleep state, measuring the fill level of the medicament in the container of the drug delivery device by means of a sensor assembly of the apparatus begins, wherein the measuring of the fill level comprises measuring the fill level between discrete time intervals, the discrete time intervals varying over time.